Premenstrual disorders: Premenstrual syndrome and premenstrual dysphoric disorder.
PMDD
PMDs
PMS
allopregnolone
serotonin
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
14
10
2022
accepted:
20
10
2022
pubmed:
2
11
2022
medline:
11
2
2023
entrez:
1
11
2022
Statut:
ppublish
Résumé
Recently, the term premenstrual disorders (PMDs), which includes premenstrual syndrome and premenstrual dysphoric disorder as a continuum, has been proposed. Although the precise etiology of PMDs remains unknown, the involvement of hormonal fluctuations is clear. The brain transmitters, serotonin and γ-amino butyric acid, also seem to be involved. Serotonin reuptake inhibitors and oral contraceptives are the current mainstay of treatment, but these are insufficient. Even the currently used prospective two-period symptom diary is not widely used in actual clinical practice, creating a major problem of discrepancy between research and clinical practice. In this review, I would like to outline the latest information and problems in the etiology, diagnosis, and treatment of PMDs, with an emphasis on promising new therapies.
Substances chimiques
Contraceptives, Oral
0
Selective Serotonin Reuptake Inhibitors
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
510-518Informations de copyright
© 2022 Japan Society of Obstetrics and Gynecology.
Références
Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218:68-74.
Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand. 2001;104:110-6.
O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14:13-21.
Hofmeister S, Bodden S. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2016;94:236-40.
Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. TR. Arlington: American Psychiatric Association; 2022.
Dr Fau R, Roy-Byrne P, Roy-Byrne P. Premenstrual syndromes: overview from a methodologic perspective. Am J Psychiatry. 1984;141:163-72.
Henz A, Ferreira CF, Oderich CL, Gallon CW, Castro JRS, Conzatti M, et al. Premenstrual syndrome diagnosis: a comparative study between the daily record of severity of problems (DRSP) and the premenstrual symptoms screening tool (PSST). Rev Bras Ginecol Obstet. 2018;40:20-5.
Craner JR, Sigmon ST, McGillicuddy ML. Does a disconnect occur between research and practice for premenstrual dysphoric disorder (PMDD) diagnostic procedures? Women Health. 2014;54:232-44.
Hantsoo L, Sajid H, Murphy L, Buchert B, Barone J, Raja S, et al. Patient experiences of health care providers in premenstrual dysphoric disorder: examining the role of provider specialty. J Womens Health (Larchmt). 2022;31:100-9.
Johnson TM. Premenstrual syndrome as a Western culture-specific disorder. Cult Med Psychiatry. 1987;11:337-56.
Dennerstein L, Lehert P, Heinemann K. Epidemiology of premenstrual symptoms and disorders. Menopause Int. 2012;18:48-51.
Qiao M, Zhang H, Liu H, Luo S, Wang T, Zhang J, et al. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China. Eur J Obstet Gynecol Reprod Biol. 2012;162:83-6.
Takeda T, Tasaka K, Sakata M, Murata Y. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women. Arch Womens Ment Health. 2006;9:209-12.
Osborn E, Wittkowski A, Brooks J, Briggs PE, O'Brien PMS. Women's experiences of receiving a diagnosis of premenstrual dysphoric disorder: a qualitative investigation. BMC Womens Health. 2020;20:242.
Steiner M, Peer M, Palova E, Freeman EW, Macdougall M, Soares CN. The premenstrual symptoms screening tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Womens Ment Health. 2011;14:77-81.
Takeda T, Koga S, Yaegashi N. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese high school students. Arch Womens Ment Health. 2010;13:535-7.
Lu D, Aleknaviciute J, Bjarnason R, Tamimi RM, Valdimarsdóttir UA, Bertone-Johnson ER. Pubertal development and risk of premenstrual disorders in young adulthood. Hum Reprod. 2021;36:455-64.
Czajkowska M, Drosdzol-Cop A, Gałązka I, Naworska B, Skrzypulec-Plinta V. Menstrual cycle and the prevalence of premenstrual syndrome/premenstrual dysphoric disorder in adolescent athletes. J Pediatr Adolesc Gynecol. 2015;28:492-8.
Takeda T, Imoto Y, Nagasawa H, Muroya M, Shiina M. Premenstrual syndrome and premenstrual dysphoric disorder in Japanese collegiate athletes. J Pediatr Adolesc Gynecol. 2015;28:215-8.
Takeda T, Imoto Y, Nagasawa H, Takeshita A, Shiina M. Stress fracture and premenstrual syndrome in Japanese adolescent athletes: a cross-sectional study. BMJ Open. 2016;6:e013103.
Takeda T, Ueno T, Uchiyama S, Shiina M. Premenstrual symptoms interference and equol production status in Japanese collegiate athletes: a cross-sectional study. J Obstet Gynaecol Res. 2018;44:488-94.
ACOG Committee Opinion No. 760: dysmenorrhea and endometriosis in the adolescent. Obstet Gynecol. 2018;132:e249-58.
Kitamura M, Takeda T, Koga S, Nagase S, Yaegashi N. Relationship between premenstrual symptoms and dysmenorrhea in Japanese high school students. Arch Womens Ment Health. 2012;15:131-3.
Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health. 2003;6:203-9.
Bentz D, Steiner M. SIPS MG: screening instrument for premenstrual symptoms. The German version of premenstrual symptoms screening tool to assess clinically relevant disturbances. Nervenarzt. 2012;83:33-9.
Câmara RA, Köhler CA, Frey BN, Hyphantis TN, Carvalho AF. Validation of the Brazilian Portuguese version of the premenstrual symptoms screening tool (PSST) and association of PSST scores with health-related quality of life. Braz J Psychiatry. 2017;39:140-6.
Mahfoud Z, Emam R, Anchassi D, Omran S, Alhaj N, al-Abdulla S, et al. Premenstrual dysphoric disorder in Arab women: validation and cultural adaptation of the Arabic version of the premenstrual screening tool. Women Health. 2019;59:631-45.
Miyaoka Y, Akimoto Y, Ueda K, Ujiie Y, Kametani M, Uchiide Y, et al. Fulfillment of the premenstrual dysphoric disorder criteria confirmed using a self-rating questionnaire among Japanese women with depressive disorders. Biopsychosoc Med. 2011;5:5.
Śliwerski A, Koszałkowska K. The influence of depression on biased diagnosis of premenstrual syndrome and premenstrual dysphoric disorder by the PSST inventory. Life (Basel). 2021;11:1278.
Jabrayilov R, Emons WHM, Sijtsma K. Comparison of classical test theory and item response theory in individual change assessment. Appl Psychol Measur. 2016;40:559-72.
Takeda T, Yoshimi K, Yamada K. Psychometric testing of the premenstrual symptoms questionnaire and the association between perceived injustice and premenstrual symptoms: a cross-sectional study among Japanese high school students. Int J Womens Health. 2020;12:755-63.
Takeda T, Yoshimi K, Kai S, Inoue F. Development and psychometric testing of a new short-form of the premenstrual symptoms questionnaire (PSQ-S). Int J Womens Health. 2022;14:899-911.
Management of premenstrual syndrome: Green-top Guideline; No. 48. BJOG. 2017;124(3):e73-e105.
Endicott J, Nee J, Harrison W. Daily record of severity of problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9:41-9.
Wu L, He Z, Zhao H, Ma D, Zhang S, Deng H, et al. Chinese version of daily record of severity of problems: reliability and validity. J Adv Nurs. 2013;69:449-56.
Takeda T, Shiina M, Chiba Y. Effectiveness of natural S-equol supplement for premenstrual symptoms: protocol of a randomised, double-blind, placebo-controlled trial. BMJ Open. 2018;8:e023314.
Takeda T, Shiina M, Yamada K. Development of the Japanese version of the daily record of severity of problems (DRSP): translation and linguistic validation. Clin Gynecol Obstet (in Japanese). 2019;73:807-11.
Takeda T, Kai S, Yoshimi K. Psychometric testing of the Japanese version of the daily record of severity of problems among Japanese women. Int J Womens Health. 2021;13:361-7.
Ikeda Y, Egawa M, Hiyoshi K, Ueno T, Ueda K, Becker CB, et al. Development of a Japanese version of the daily record of severity of problems for diagnosing premenstrual syndrome. Womens Health Rep (New Rochelle). 2020;1:11-6.
Ikeda Y, Egawa M, Okamoto K, Mandai M, Takahashi Y, Nakayama T. The reliability and validity of the Japanese version of the daily record of severity of problems (J-DRSP) and development of a short-form version (J-DRSP [SF]) to assess symptoms of premenstrual syndrome among Japanese women. Biopsychosoc Med. 2021;15:6.
Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209-16.
Schmidt PJ, Martinez PE, Nieman LK, Koziol DE, Thompson KD, Schenkel L, et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry. 2017;174:980-9.
Nevatte T, O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013;16:279-91.
Lin SH, Lee LT, Yang YK. Serotonin and mental disorders: a concise review on molecular neuroimaging evidence. Clin Psychopharmacol Neurosci. 2014;12:196-202.
McQueen JK, Wilson H, Fink G. Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Brain Res Mol Brain Res. 1997;45:13-23.
Bertrand PP, Paranavitane UT, Chavez C, Gogos A, Jones M, van den Buuse M. The effect of low estrogen state on serotonin transporter function in mouse hippocampus: a behavioral and electrochemical study. Brain Res. 2005;1064:10-20.
Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord. 1994;32:37-44.
Dubol M, Epperson CN, Lanzenberger R, Sundström-Poromaa I, Comasco E. Neuroimaging premenstrual dysphoric disorder: a systematic and critical review. Front Neuroendocrinol. 2020;57:100838.
Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordström AL. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res. 2006;148:185-93.
Foster AC, Kemp JA. Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006;6:7-17.
Schüle C, Nothdurfter C, Rupprecht R. The role of allopregnanolone in depression and anxiety. Prog Neurobiol. 2014;113:79-87.
Schneider T, Popik P. An animal model of premenstrual dysphoric disorder sensitive to antidepressants. Curr Protoc Neurosci. 2009;9:31.
Li Y, Pehrson AL, Budac DP, Sánchez C, Gulinello M. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. Behav Brain Res. 2012;234:238-47.
Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol. 1997;90:709-14.
Monteleone P, Luisi S, Tonetti A, Bernardi F, Genazzani AD, Luisi M, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol. 2000;142:269-73.
Martinez PE, Rubinow DR, Nieman LK, Koziol DE, Morrow AL, Schiller CE, et al. 5α-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology. 2016;41:1093-102.
Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, et al. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010): a randomized controlled trial. Psychoneuroendocrinology. 2017;80:46-55.
Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry. 2002;59:851-8.
Liu B, Wang G, Gao D, Gao F, Zhao B, Qiao M, et al. Alterations of GABA and glutamate-glutamine levels in premenstrual dysphoric disorder: a 3T proton magnetic resonance spectroscopy study. Psychiatry Res. 2015;231:64-70.
Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology. 2008;33:73-83.
Elfving B, Buttenschøn HN, Foldager L, Poulsen PHP, Andersen JH, Grynderup MB, et al. Depression, the Val66Met polymorphism, age, and gender influence the serum BDNF level. J Psychiatr Res. 2012;46:1118-25.
Harrisberger F, Smieskova R, Schmidt A, Lenz C, Walter A, Wittfeld K, et al. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2015;55:107-18.
Comasco E, Hahn A, Ganger S, Gingnell M, Bannbers E, Oreland L, et al. Emotional fronto-cingulate cortex activation and brain derived neurotrophic factor polymorphism in premenstrual dysphoric disorder. Hum Brain Mapp. 2014;35:4450-8.
Oral E, Kirkan TS, Yildirim A, Kotan Z, Cansever Z, Ozcan H, et al. Serum brain-derived neurotrophic factor differences between the luteal and follicular phases in premenstrual dysphoric disorder. Gen Hosp Psychiatry. 2015;37:266-72.
Cubeddu A, Bucci F, Giannini A, Russo M, Daino D, Russo N, et al. Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology. 2011;36:523-30.
Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, et al. Possible association of Bifidobacterium and lactobacillus in the gut microbiota of patients with major depressive disorder. J Affect Disord. 2016;202:254-7.
Morais LH, HLT S, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol. 2021;19:241-55.
Tian P, Wang G, Zhao J, Zhang H, Chen W. Bifidobacterium with the role of 5-hydroxytryptophan synthesis regulation alleviates the symptom of depression and related microbiota dysbiosis. J Nutr Biochem. 2019;66:43-51.
Sanada K, Nakajima S, Kurokawa S, Barceló-Soler A, Ikuse D, Hirata A, et al. Gut microbiota and major depressive disorder: a systematic review and meta-analysis. J Affect Disord. 2020;266:1-13.
Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13:701-12.
Takeda T, Yoshimi K, Kai S, Ozawa G, Yamada K, Hiramatsu K. Characteristics of the gut microbiota in women with premenstrual symptoms: a cross-sectional study. PLoS One. 2022;17:e0268466.
Lustyk MK, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2009;12:85-96.
Hunter MS, Ussher JM, Browne SJ, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol. 2002;23:193-9.
Sayegh R, Schiff I, Wurtman J, Spiers P, McDermott J, Wurtman R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol. 1995;86:520-8.
Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;2013:CD001396.
Ismaili E, Walsh S, O'Brien PMS, Bäckström T, Brown C, Dennerstein L, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch Womens Ment Health. 2016;19:953-8.
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiat. 2015;72:1037-44.
Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2:Cd006586.
Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006;195:1311-9.
Machado RB, Pompei LM, Badalotti M, Ferriani R, Cruz AM, Nahas E, et al. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial. Eur J Contracept Reprod Health Care. 2017;22:11-6.
Mezrow G, Shoupe D, Spicer D, Lobo R, Leung B, Pike M. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril. 1994;62:932-7.
Mortola JF. Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome. Clin Obstet Gynecol. 1993;36:753-63.
Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ (Clin Res Ed). 1999;318:1375-81.
Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual syndrome study group. Am J Obstet Gynecol. 1998;179:444-52.
Yonkers KA, Pearlstein TB, Gotman N. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. J Clin Psychopharmacol. 2013;33:614-20.
Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217:150-66.
Takamatsu K, Ogawa M, Obayashi S, Takeda T, Terauchi M, Higuchi T, et al. A multicenter, randomized, double-blind, placebo-controlled trial to investigate the effects of kamishoyosan, a traditional Japanese medicine, on menopausal symptoms: the KOSMOS study. Evid Based Complement Alternat Med. 2021;2021:8856149.
Yamada K, Kanba S. Effectiveness of kamishoyosan for premenstrual dysphoric disorder: open-labeled pilot study. Psychiatry Clin Neurosci. 2007;61:323-5.
Shimizu S, Ishino Y, Takeda T, Tohyama M, Miyata S. Antidepressive effects of kamishoyosan through 5-HT1Areceptor and PKA-CREB-BDNF signaling in the hippocampus in postmenopausal depression-model mice. Evid Based Complement Alternat Med. 2019;2019:9475384.
Casson P, Hahn PM, van Vugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol. 1990;162:99-105.
Comasco E, Kopp Kallner H, Bixo M, Hirschberg AL, Nyback S, de Grauw H, et al. Ulipristal acetate for treatment of premenstrual dysphoric disorder: a proof-of-concept randomized controlled trial. Am J Psychiatry. 2021;178:256-65.
Whitaker LH, Williams AR, Critchley HO. Selective progesterone receptor modulators. Curr Opin Obstet Gynecol. 2014;26:237-42.
Rabe T, Saenger N, Ebert AD, Roemer T, Tinneberg H-R, de Wilde RL, et al. Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate. Biomed Res Int. 2018;2018:1374821.
Mori Y, Kakuta T, Miyakogawa T, Takekoshi S, Yuzawa H, Kobayashi H, et al. Effect of scavenging circulating reactive carbonyls by oral pyridoxamine in uremic rats on peritoneal dialysis. Ther Apher Dial. 2016;20:645-54.
Sherif FM, Ahmed SS. Basic aspects of GABA-transaminase in neuropsychiatric disorders. Clin Biochem. 1995;28:145-54.
Itokawa M, Miyashita M, Arai M, Dan T, Takahashi K, Tokunaga T, et al. Pyridoxamine: a novel treatment for schizophrenia with enhanced carbonyl stress. Psychiatry Clin Neurosci. 2018;72:35-44.